Cognition Therapeutics

CGTX

Market cap $106M

PURCHASE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi intends to present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13th at 3:00 p.m. Eastern Time. During her presentation, Ms. Ricciardi will provide an update on progress of the Company's development programs for Alzheimer's disease and dementia with Lewy bodies (DLB).

Advancing Zervimesine (CT1812) towards late-stage trials for  dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 PURCHASE, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.  (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders, has published CEO Lisa Ricciardi's Letter to Shareholders.

Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript

-Advancing zervimesine clinical development in DLB psychosis –  - Meeting with FDA Division of Psychiatry expected by mid-2026 - - Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y.

PURCHASE, N.Y., March 23, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), plans to release financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 26, 2026 before the market open.

PURCHASE, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 COG1201 SHIMMER study (NCT05225415) of zervimesine (CT1812) in dementia with Lewy bodies (DLB) at the AD/PD™ 2026 Alzheimer's & Parkinson's Diseases Conference. The conference is being conducted March 17-21, 2026 in Copenhagen, Denmark. The analysis focuses on Zervimesine's treatment effects on the behavioral and psychiatric symptoms most commonly associated with DLB.

We believe regulatory strategy expedites development of potential first treatment to address DLB psychosis We believe regulatory strategy expedites development of potential first treatment to address DLB psychosis

PURCHASE, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has extended the duration of the expanded access program (EAP) for dementia with Lewy bodies (DLB). The program, which was originally expected to provide each participant with twelve months of treatment, will now allow several more months of treatment.

PURCHASE, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a Type C meeting with the U.S. Food and Drug Administration (FDA) on January 21, 2026. The objective of this meeting was to review plans for the proposed Phase 2b study of zervimesine in dementia with Lewy bodies (DLB), a disease with no FDA-approved therapies.

- Zervimesine exhibited meaningful improvement in behavioral, functional, cognitive, and movement measures compared to placebo - - Zervimesine exhibited meaningful improvement in behavioral, functional, cognitive, and movement measures compared to placebo -